Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Frequently asked questions
What sector does Adaptimmune Therapeutics plc (ADAPY) operate in?
Adaptimmune Therapeutics plc belongs to the Other sector and operates in the Biotechnology industry.
What is Adaptimmune Therapeutics plc (ADAPY) current stock price?
As of the latest data, Adaptimmune Therapeutics plc stock price is $0.03, with a previous close of $0.03.
What is Adaptimmune Therapeutics plc (ADAPY) current market capitalization?
Adaptimmune Therapeutics plc market cap is approximately 6.65 million.
What is Adaptimmune Therapeutics plc (ADAPY) Earnings Per Share (EPS)?
The trailing EPS is -$0.67, and the forward EPS is -$0.50.
Does Adaptimmune Therapeutics plc (ADAPY) pay dividends?
No. Adaptimmune Therapeutics plc does not pay a dividend.
What is Adaptimmune Therapeutics plc (ADAPY) beta (volatility) score?
Adaptimmune Therapeutics plc has a beta of 0.750, indicating lower volatility than the overall market.